We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

104 hedge funds and large institutions have $156M invested in ImmunityBio in 2020 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 23 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more capital invested

Capital invested by funds: $70.7M → $156M (+$85M)

48% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 21

39% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 23

9% more funds holding

Funds holding: 95 → 104 (+9)

1.31% more ownership

Funds ownership: 9.43% → 10.75% (+1.3%)

59% less call options, than puts

Call options by funds: $9.93M | Put options by funds: $24.1M

Holders
104
Holders Change
+9
Holders Change %
+9.47%
% of All Funds
1.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
32
Reduced
23
Closed
21
Calls
$9.93M
Puts
$24.1M
Net Calls
-$14.1M
Net Calls Change
-$12M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11.5M
2
Invesco
Invesco
Georgia
+$3.31M
3
JP Morgan Chase
JP Morgan Chase
New York
+$2.97M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.55M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.51M

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$4.28M
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$2.98M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.94M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$977K
5
SSA
Schonfeld Strategic Advisors
New York
-$873K

IBRX Hedge Fund Activity: Q4 2020 in Review

104 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2020, worth a combined $156M — up 120% from $70.7M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new IBRX positions and 21 closed out — a net gain of 10 holders — while 32 added to existing stakes and 23 trimmed.

The largest buyer was BlackRock, adding an estimated $11.5M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $4.28M sold.

  • 104 institutional investors held ImmunityBio (IBRX) as of Q4 2020, up from 95 in Q3 2020.
  • Funds reported $156M of ImmunityBio stock for Q4 2020, up 120% quarter-over-quarter.
  • 31 funds opened new ImmunityBio positions in Q4 2020 and 21 closed out, a net change of +10 holders.
  • The largest ImmunityBio buyer in Q4 2020 was BlackRock, an estimated $11.5M added.
  • The largest ImmunityBio seller in Q4 2020 was Two Sigma Investments, an estimated $4.28M sold.

Based on aggregated 13F filings for Q4 2020.